REGENXBIO (RGNX) to Release Earnings on Tuesday

REGENXBIO (NASDAQ:RGNX) is expected to post its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect REGENXBIO to post earnings of ($1.19) per share and revenue of $23.70 million for the quarter.

REGENXBIO Trading Down 1.2 %

RGNX opened at $7.27 on Friday. The company has a 50 day moving average of $7.70 and a 200 day moving average of $9.61. REGENXBIO has a 12 month low of $6.56 and a 12 month high of $28.80. The company has a market cap of $360.16 million, a PE ratio of -1.45 and a beta of 1.29.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Raymond James assumed coverage on shares of REGENXBIO in a report on Friday, February 7th. They issued an “outperform” rating and a $27.00 price target for the company. Chardan Capital reissued a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a report on Wednesday, November 20th. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of REGENXBIO in a report on Wednesday, January 15th. StockNews.com downgraded shares of REGENXBIO from a “hold” rating to a “sell” rating in a report on Saturday, February 15th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $30.00 price target on shares of REGENXBIO in a report on Tuesday, January 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $33.45.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.